Table 3.
Demographic, pathological and clinical data stratified by TDP-43 stage
| Stage 1 (N = 31) |
Stage 2 (N = 46) |
Stage 3 (N = 18) |
Stage 4 (N = 49) |
Stage 5 (N = 34) |
Stage 6 (N = 15) |
Trend test P-value |
|
|---|---|---|---|---|---|---|---|
|
| |||||||
| No. Female (%) | 20 (65) | 29 (63) | 12 (67) | 31 (63) | 21 (62) | 10 (67) | 0.96 |
| Education, yrs | 14 (12, 20) | 14 (8, 20) | 15 (8, 20) | 12 (8, 20) | 13 (8, 20) | 13 (9, 20) | 0.26 |
| APOE ε4 carrier (%) | 25 (81) | 25 (57) | 11 (61) | 29 (62) | 16 (50) | 10 (67) | 0.13 |
| Age at onset, yrs | 74 (56, 91) | 76 (58, 102) | 82 (50, 96) | 78 (63, 97) | 80 (60, 94) | 76 (54, 96) | 0.10 |
| Time from onset to death, yrs | 8 (2, 27) | 10 (2, 20) | 8 (3, 13) | 11 (2, 19) | 11 (3, 27) | 9 (6, 18) | 0.14 |
| Age at death, yrs | 85 (71, 100) | 87 (65, 105) | 88 (56, 101) | 88 (76, 104) | 90 (70, 101) | 85 (65, 104) | 0.01 |
| Cognitively abnormal at death (%) | 30 (97) | 42 (93) | 18 (100) | 48 (100) | 34 (100) | 15 (100) | 0.06 |
| Diagnosis (%) | 0.22 | ||||||
| CN | 2 (6) | 5 (11) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | |
| MCI | 3 (10) | 1 (2) | 1 (6) | 2 (4) | 3 (9) | 2 (13) | |
| Other Dementia | 26 (84) | 39 (87) | 17 (94) | 46 (96) | 30 (91) | 13 (87) | |
| Braak stage (%) | 0.84 | ||||||
| 4 | 6 (19) | 7 (15) | 4 (22) | 8 (16) | 5 (15) | 3 (20) | |
| 5 | 6 (19) | 15 (33) | 6 (33) | 13 (27) | 11 (32) | 4 (27) | |
| 6 | 19 (61) | 24 (52) | 8 (44) | 28 (57) | 18 (53) | 8 (53) | |
| CERAD Frequent (%) | 22 (71) | 28 (62) | 11 (61) | 31 (63) | 18 (53) | 12 (80) | 0.64 |
| Infarction (%) | 11 (35) | 9 (20) | 3 (17) | 16 (33) | 9 (26) | 5 (33) | 0.80 |
| Hippocampal sclerosis positive (%) | 4 (13) | 3 (7) | 4 (22) | 29 (60) | 25 (74) | 13 (87) | <0.001 |
| Lewy bodies positive (%) | 7 (23) | 18 (40) | 8 (44) | 15 (31) | 13 (38) | 5 (33) | 0.59 |
| MMSE | 26 (16, 29) | 24 (13, 30) | 24 (7, 30) | 23 (11, 29) | 25 (12, 29) | 23 (13, 30) | 0.22 |
| Total UPDRS | 0 (0, 6) | 0 (0, 13) | 2 (0, 28) | 2 (0, 10) | 0 (0, 8) | 0 (0, 8) | 0.56 |
| Boston Naming Test | 47 (2, 58) | 46 (12, 59) | 43 (22, 54) | 39 (10, 59) | 38 (9, 57) | 40 (8, 59) | 0.06 |
| WAIS-Block Design | 17 (2, 36) | 14 (0, 35) | 12 (0, 22) | 10 (0, 35) | 12 (0, 28) | 14 (5, 23) | 0.048 |
| COWAT total raw | 33 (5, 66) | 24 (7, 59) | 30 (15, 58) | 24 (9, 54) | 30 (6, 43) | 24 (0, 51) | 0.06 |
| AVLT Delayed Recall | 2 (0, 9) | 0 (0, 8) | 0 (0, 3) | 0 (0, 6) | 0 (0, 6) | 0 (0, 5) | 0.01 |
MMSE = Mini-Mental State Examination; UPDRS = Unified Parkinson’s Disease Rating Scale; WAIS = Wechsler Adult Intelligence Scale; COWAT = Control Oral Word Association Test; AVLT = Auditory Verbal Learning Test.
Unless otherwise specific data shown as median (range). P-values were from Spearman's and Wilcoxon rank sum tests.